Free Trial

Curaleaf (OTCMKTS:CURLF) Shares Gap Up - Here's Why

Curaleaf logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Curaleaf gapped up pre-market, opening at $2.28 after a $2.15 close, though it last traded at $2.13 on volume of 86,856 shares.
  • Several analysts have raised ratings—Zacks to Hold, ATB Cormark to Outperform and Alliance Global Partners reaffirming Buy—leaving Curaleaf with a MarketBeat consensus rating of Buy.
  • The company beat the quarter's estimates (EPS -$0.05 vs. -$0.08; revenue $333.07M vs. $328.70M) but remains unprofitable with a negative net margin (-18.08%) and analysts forecasting -$0.25 EPS for the year.
  • Five stocks we like better than Curaleaf.

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $2.15, but opened at $2.28. Curaleaf shares last traded at $2.13, with a volume of 86,856 shares changing hands.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Zacks Research upgraded Curaleaf from a "strong sell" rating to a "hold" rating in a research note on Thursday, January 1st. ATB Cormark Capital Markets upgraded Curaleaf to an "outperform" rating in a report on Tuesday, December 2nd. Finally, Alliance Global Partners reissued a "buy" rating on shares of Curaleaf in a research report on Monday, December 22nd. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Curaleaf currently has a consensus rating of "Buy".

View Our Latest Analysis on Curaleaf

Curaleaf Stock Performance

The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -7.22 and a beta of 0.71. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.76 and a current ratio of 1.52. The stock's fifty day moving average is $2.36 and its two-hundred day moving average is $2.61.

Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03. The company had revenue of $333.07 million during the quarter, compared to analysts' expectations of $328.70 million. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 23.17%. Analysts forecast that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.

Curaleaf Company Profile

(Get Free Report)

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company's vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf's product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines